These two biotechs could have a tortoise-and-hare kind of race going on.
News & Analysis: Intercept Pharmaceuticals
Intercept's shares continued to slide last month. Here's why.
The biotech turned in another strong quarterly performance with rising sales for Ocaliva and a regulatory filing for a new indication on the way.
ICPT earnings call for the period ending March 31, 2019.
Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.
GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.
The complete presentation of results from the Regenerate trial wasn't exactly what investors were expecting.
Gloomy views of these businesses sent their stocks lower.
These two biotechs have been stellar growth vehicles for investors, but only one stock is worth buying right now.
These biotech stocks could have a lot of room to run.